• FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • Storage bufferPreservative: 0.09% Sodium Azide
    Constituents: 20mM PBS, 150mM Sodium chloride, pH 7.2
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Clonality Polyclonal
  • IsotypeIgG
  • Research Areas


Our Abpromise guarantee covers the use of ab60978 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesWB: Use at an assay dependent dilution. Detects bands of approximately 20 and 40 kDa (predicted molecular weight: 20 kDa). We have no information regarding the 40 kDa band.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionInhibits the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater affinity than decoy receptor IL1R2; however, the physiological relevance of the latter association is unsure.
    • Tissue specificityThe intracellular form of IL1RN is predominantly expressed in epithelial cells.
    • Involvement in diseaseGenetic variation in IL1RN is associated with susceptibility to microvascular complications of diabetes type 4 (MVCD4) [MIM:612628]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
      Defects in IL1RN are the cause of interleukin 1 receptor antagonist deficiency (DIRA) [MIM:612852]; also known as deficiency of interleukin 1 receptor antagonist. Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T-cells. DIRA is a rare, autosomal recessive, genetic autoinflammatory disease that results in sterile multifocal osteomyelitis (bone inflammation in multiple places), periostitis (inflammation of the membrane surrounding the bones), and pustulosis (due to skin inflammation) from birth.
    • Cellular localizationCytoplasm and Secreted.
    • Information by UniProt
    • Database links
    • Alternative names
      • DIRA antibody
      • ICIL 1RA antibody
      • ICIL-1RA antibody
      • ICIL1RA antibody
      • IL-1ra antibody
      • IL-1ra3 antibody
      • IL-1RN antibody
      • IL1 inhibitor antibody
      • IL1F3 antibody
      • IL1RA antibody
      • IL1RA_HUMAN antibody
      • IL1RN (IL1F3) antibody
      • IL1RN antibody
      • Interleukin 1 receptor antagonist antibody
      • Interleukin 1 Receptor Antagonist Protein antibody
      • Interleukin-1 receptor antagonist protein antibody
      • Intracellular IL 1 receptor antagonist type II antibody
      • Intracellular interleukin 1 receptor antagonist (icIL 1ra) antibody
      • IRAP antibody
      • MGC10430 antibody
      • MVCD4 antibody
      • Type II interleukin 1 receptor antagonist antibody
      see all

    Anti-IL1RA antibody images

    • Anti-IL1RA antibody (ab60978) at 5 µg/ml + Recombinant human IL-1Ra. at 0.1 µg

      anti-sheep IgG - HRP at 1/10000 dilution

      Predicted band size : 20 kDa
      Observed band size : 20 kDa
      Additional bands at : ~40 kDa (possible dimer).

    References for Anti-IL1RA antibody (ab60978)

    ab60978 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab60978.
    Please use the links above to contact us or submit feedback about this product.